Nouvelle déclaration d'incident
No de la demande: 2019-6459
Numéro de référence du titulaire d'homologation: USA-BAYERBAH-2019-US0061768 (Report 604621)
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer inc
Adresse: 2920 Matheson Blvd
Ville: Mississaugua
État: ON
Pays: Canada
Code postal /Zip: L4W 5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: ILLINOIS
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-155
Nom du produit: Seresto Small Dog
Autre (préciser)
COLLAROui
Autres unités: COLLAR
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Dog / Chien
Jack Russell Terrier
1
Femme
8
6.668
kg
Cutanée
>3 days <=1 wk / >3 jours <=1 sem
>24 hrs <=3 days / >24 h <=3 jours
Système
Unknown / Inconnu
Oui
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 05 Oct 2019, the dog exhibited vomiting and itchy and watery eyes. On 07 Oct 2019, the dog exhibited multiple episodes of vomiting and diarrhea. On 09 Oct 2019, the owner removed the collar. On 10 Oct 2019, the dog was examined by a veterinarian and a blood chemistry, electrolytes and blood count performed revealed an elevated red blood cell count of 9.16%, hemoglobin count of 21.g/dl, decreased lymphocytes 0.87 K/uL, and mild increased glucose at 153 mg/dl. A flourscein stain eye test was performed and the dog was diagnosed with bilateral corneal ulcers. The dog was administered 0.7 ml of cefovecin sodium subcutaneously, unspecified dose of oral nitenpyram and 150 ml of subcutaneous fluids. The clinical signs continued. On 13 Oct 2019, the dog was bathed with dish soap. On 14 Oct 2019, the dog exhibited lethargy. The dog was re-evaluated by the veterinarian, radiographs performed revealed continued undigested food and gas in the colon and small intestine. The dog was diagnosed with aspiration pneumonia, megaesophagus, bilateral corneal ulcers and was administered an injection of 0.7 ml cefovecin sodium and 160 ml of subcutaneous fluids. The dog was placed on tobramycin ophthalmic drops 1 drop in each eye every 12 hours. The clinical signs continued. On 16 Oct 2019, the dog was re-evaluated by the veterinarian, exhibited pruritus, radiographs of the abdomen and chest were performed and revealed an enlarged stomach, an interstitial pattern in the right caudal lung field. The dog was started on 25 mg oral marbofloxacin once a day, 500 mg of oral sucralfate twice a day and 5 mg of famotidine twice daily. The clinical signs continued. Owner administered unknown dosage of diphenhydramine orally. On 18 Oct 2019, the dog was evaluated by a new veterinarian and diagnosed with a grade 3/6 left systolic heart murmur, bilateral ocular discharge and moderate hyperemia. Radiographs performed and reveled a consolidation of the right lung, gas in the esophagus and stomach. The dog was administered an unspecified amount of subcutaneous fluids and placed on oral chewable amoxicillin/trihydrate/clavulanic acid. On approximately 21 Oct 2019, the dog had 2 seizures and died at home. No necropsy was performed.
Mort
O - Unclassifiable/unassessable Reported eye disorders of itchy, watery eyes, later reported corneal ulcers and ocular discharge are not expected after topical product application. No eye exposure of product reported. Time to onset for eye disorders is short, though. Reported digestive signs of vomiting and diarrhoea are unspecific and may have numerous other causes (e.g. gastrointestinal infection, dietary incompatibility). Though mild gastrointestinal signs may occur shortly after product application, they are not expected to appear with long time to onset. Pruritus on other than the application site is not typically seen with topical product administration. Other causes (e.g. allergies) are more probable although not described. Diagnosed abnormal blood parameters and further reported such as gastric distension, pneumonia, megaesophagus, hyperemia, abnormal radiograph findings, heart murmur, seizure and death are not expected after topical product application, as these are inconsistent with the pharmaco-toxicological product profile. Moreover, these signs occurred long time after removal of collar, hence not related to the product. The collar was worn only for some days, however majority of signs, in particular severe signs and death, occurred long time after collar removal. The product has no systemic efficacy and thus other causes are more likely. Though a product relation is considered rather unlikely, due to limited information a relation for the case is considered unassessable.